Search Results - "MD Anderson Cancer Center"

Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure–response analysis of a Phase III study by Wang X, Roy A, Hochhaus A, Kantarjian HM, Chen TT, Shah NP

Connect to this object online.

Novel Clinically Weight-Optimized Dynamic Conformal Arcs (WO-DCA) for Liver SBRT: A Comparison with Volumetric Modulated Arc Therapy (VMAT) by Saglam Y, Bolukbasi Y, Atasoy AI, Karakose F, Budak M, Alpan V, Topkan E, Selek U

Connect to this object online.

Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells by Kim YW, Kim EY, Jeon D, Liu JL, Kim H, Choi JW, Ahn WS

Connect to this object online.

GSTM1 copy number and promoter haplotype as predictors for risk of recurrence and/or second primary tumor in patients with head and neck cancer by Zhang X, Huang M, Wu X, Kadlubar S, Lin J, Yu X, Fan C, Ning B, Kadlubar FF

Connect to this object online.

Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function by Li Y, Wang X, O'Mara E, Dimopoulos MA, Sonneveld P, Weisel KC, Matous J, Siegel DS, Shah JJ, Kueenburg E, Sternas L, Cavanaugh C, Zaki M, Palmisano M, Zhou S

Connect to this object online.

Low Pre-ChemoradiotherapyPan-Immune-Inflammation Value (PIV) Measures Predict Better Survival Outcomes in Locally Advanced Pancreatic Adenocarcinomas by Topkan E, Selek U, Kucuk A, Pehlivan B

Connect to this object online.

Pretreatment Systemic Immune-Inflammation Index Predict Needs for Teeth Extractions for Locally Advanced Head and Neck Cancer Patients Undergoing Concurrent Chemoradiotherapy by Yilmaz B, Somay E, Selek U, Topkan E

Connect to this object online.

Reverse transcription loop-mediated isothermal amplification (RT-LAMP) for point-of-care detection of SARS-CoV-2: a clinical study to evaluate agreement with RT-qPCR by Mary Natoli, PhD, Kathryn Kundrod, PhD, Megan Chang, BA, Chelsey Smith, BE, Sai Paul, BS, Karen Eldin, MD, Keyur Patel, MD, Ellen Baker, MD, Kathleen Schmeler, MD, Rebecca Richards-Kortum, PhD

Connect to this object online.

High RRM2 Correlates with Mitochondrial and Immune Responses in the Eosinophilic Subtype of Clear Cell Renal Cell Carcinoma by Zhu X, Al-danakh A, Jian Y, Safi M, Luo S, Chen Q, Wang S, Yang D

Connect to this object online.

Construction of the Interaction Network of Hub Genes in the Progression of Barrett’s Esophagus to Esophageal Adenocarcinoma by Li K, Duan P, He H, Du R, Wang Q, Gong P, Bian H

Connect to this object online.

Programação by Revista Brasileira de Medicina de Família e Comunidade RBMFC

Connect to this object online.

High Measures of Pre-Chemoradiotherapy Platelet-to-Albumin Ratio Indicates Poor Prognosis in Locally Advanced Pancreatic Cancer Patients by Kucuk A, Topkan E, Selek U, Haksoyler V, Mertsoylu H, Besen AA, Pehlivan B

Connect to this object online.

The Prognostic Significance of Novel Pancreas Cancer Prognostic Index in Unresectable Locally Advanced Pancreas Cancers Treated with Definitive Concurrent Chemoradiotherapy by Topkan E, Selek U, Pehlivan B, Kucuk A, Haksoyler V, Kilic Durankus N, Sezen D, Bolukbasi Y

Connect to this object online.

Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain Amyloidosis by Gertz M, Abonour R, Gibbs SN, Finkel M, Landau H, Lentzsch S, Lin G, Mahindra A, Quock T, Rosenbaum C, Rosenzweig M, Sidana S, Tuchman SA, Witteles R, Yermilov I, Broder MS

Connect to this object online.

Programação by Revista Brasileira de Medicina de Família e Comunidade RBMFC

Connect to this object online.

Relevance of PD-L1 Non-Coding Polymorphisms on the Prognosis of a Genetically Admixed NSCLC Cohort by Machado-Rugolo J, Gutierrez Prieto T, Fabro AT, Parra Cuentas ER, Sá VK, Baldavira CM, Rainho CA, Castelli EC, Farhat C, Takagaki TY, Nagai MA, Capelozzi VL

Connect to this object online.

Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues by Wolin EM, Jarzab B, Eriksson B, Walter T, Toumpanakis C, Morse MA, Tomassetti P, Weber MM, Fogelman DR, Ramage J, Poon D, Gadbaw B, Li J, Pasieka JL, Mahamat A, Swahn F, Newell-Price J, Mansoor W, Öberg K

Connect to this object online.